Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 7Non-Muscle Invasive Bladder Neoplasms 5Recurrence 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Melanoma 1Carcinoma in Situ 1

Interventions

pembrolizumab 180Cisplatin 44Paclitaxel 41Carboplatin 41lenvatinib 31Docetaxel 22Pemetrexed 20Fluorouracil 19Capecitabine 16Gemcitabine 15Saline Solution 13Oxaliplatin 13Albumin-Bound Paclitaxel 10epacadostat 9130-nm albumin-bound paclitaxel 9Leucovorin 8Cetuximab 8olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6belzutifan 5Dexamethasone 5enzalutamide 4trifluridine tipiracil drug combination 3regorafenib 3patritumab deruxtecan 3enfortumab vedotin 3durvalumab 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Parkinson Disease 4, Autosomal Dominant Lewy Body × BCG Vaccine × Clear all
NCT03711032 2026-05-01

MK-3475-676

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
1,397 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

Data powered by HemOnc (CC BY 4.0) Colophon âš¡